Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

Registrati

Quotazioni in diretta

TYRA Tyra Biosciences Inc

15,80

-0,11 (-0,69%)

23 Gen 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

This is a family trust that files with with three other family trusts as well as Todd Harris.

Date of Notice

09/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/05/2022

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Ryan Harris, TTEE

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Tyra Biosciences (NASDAQ:TYRA)
Storico
Da Dic 2024 a Gen 2025

Clicca qui per i Grafici di Tyra Biosciences

Grafico Azioni Tyra Biosciences (NASDAQ:TYRA)
Storico
Da Gen 2024 a Gen 2025

Clicca qui per i Grafici di Tyra Biosciences

Notizie Tyra Biosciences Inc - TYRA

Form 144 - Report of proposed sale of securities
Giovedì 23 Gennaio 2025 (6 ore fa) • Edgar (US Regulatory)

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
Mercoledì 22 Gennaio 2025 (16 ore fa) • PR Newswire (US)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Venerdì 10 Gennaio 2025 (2 settimane fa) • PR Newswire (US)

Form 144 - Report of proposed sale of securities
Lunedì 9 Dicembre 2024 (1 mese fa) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Sabatp 7 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Giovedì 5 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 3 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 20 Novembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Mercoledì 20 Novembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Giovedì 14 Novembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Tyra Biosciences to Present at Upcoming Investor Conferences
Mercoledì 13 Novembre 2024 (2 mesi fa) • PR Newswire (US)

Form 8-K - Current report
Giovedì 7 Novembre 2024 (3 mesi fa) • Edgar (US Regulatory)

Più Tyra Biosciences Inc Articoli Notizie

Standard Chartered

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea